Objective Rheumatoid arthritis (RA) patients have a doubled risk for cardiovascular (CV) disease, largely independent of traditional CV risk factors. Renal dysfunction is associated with CV morbidity and mortality in the general population, but data regarding this association in RA are lacking. We investigated the association between renal function and CV events in RA.
Introduction
In recent years rheumatoid arthritis (RA) has been linked with an increased cardiovascular (CV) disease morbidity and mortality, an association that persists after adjustment for traditional CV disease risk factors (such as age, gender, smoking, blood pressure and hypercholesterolemia).(1) Epidemiological evidence suggests that other risk factors may be responsible for the excess CV risk. (2, 3) However, the causative mechanism behind this increased CV disease risk is still mostly unknown.
A recent meta-analysis clearly illustrates that renal dysfunction is a strong and independent CV risk factor in the general population (4) , but data on the association between renal dysfunction and CV disease in RA is currently lacking. Renal dysfunction is also common among RA patients (5) and this might be attributed to use of antiinflammatory medication (6) , extra-articular manifestations (including amyloidosis and/or glomerulonephritis) (7), a higher prevalence of either diabetes mellitus or hypertension in RA (6, 8) or chronic inflammation. (9) A necropsy study found that 90% of RA-patients had benign nephrosclerosis that correlated with arteriosclerosis. (10) In the present study, we investigate the association between renal dysfunction and CV disease in RA patients using data from the prospective CARRÉ study, in the context of known traditional risk factors.
Methods

CARRÉ study
The CARRÉ study is a prospective cohort of patients with RA, in whom CV events and concurrent risk factors were investigated. For this study we used data from the 3 year follow-up period.(11) A total of 353 patients aged 50-75 years who fulfilled the American College of Rheumatology criteria of 1987 for RA (12) were enrolled in this study. Follow-up duration was calculated as time from enrolment in the study until follow-up measurement or occurrence of a (non-) fatal CV event. During the follow-up period, all CV events were recorded. Adjudication of CV events was performed on the basis of standardized criteria by an independent trained person according to the ICD-9 codes for myocardial infarction (MI) (410.0-9), stroke (436) or transient ischemic attack (TIA) (435.9), a history of peripheral arterial reconstruction, carotid endarterectomy, percutaneous coronary intervention (PCI) (8036), coronary artery by-pass surgery (CABG) (8038) and sudden death, cause unknown (798). The local ethics committee approved the study protocol and all participants gave written informed consent.
Baseline characteristics
Blood pressure, length, weight, waist-and hip circumference, presence of subcutaneous nodules, smoking habits, medication use, co-morbidity, previous CV disease, disease activity score of 28 joints (DAS28) and the functional (disability) status were all assessed according to protocol during intake and physical examination. Hypertension was defined as a blood pressure more then 140/90 mmHg and/or use of antihypertensive medication.
In addition, rheumatoid factor positivity, inflammatory markers, serum creatinine levels and lipid levels were determined in fasting blood samples and urinary protein excretion was determined from a second void urine sample.(11) Atherogenic index was calculated as the ratio between total cholesterol and HDL-cholesterol. 10-year CV risk was calculated using the Systematic Coronary Risk Evaluation (SCORE) formula. (13) 
Renal function
Serum creatinine was measured in 349 patients at baseline and 261 patients at follow-up. 
Results
Baseline characteristics
Baseline characteristics are shown in table 1 for the total study population and stratified for patients with and without a CV event. Patients with a CV event were significantly older, more often male, smoker, more often had hypertension, hypercholesterolemia and previous CV disease. In addition, they used statins and antihypertensive medication more frequently. 
Follow-up and cardiovascular events
Mean follow-up duration was 2.7 ± 0.8 years. Nineteen of the 349 participants were lost to follow-up due to moving away from the area or that they stopped participating in the study. Of the remaining 330 participants 23 developed a CV disease event (7%). Of these, eight patients were diagnosed as having a myocardial infarction (all non-fatal), three patients underwent elective PCI and two patients underwent elective CABG, two patients were diagnosed with ischaemic stroke (all non-fatal) and four patients as having a transient ischaemic attack, two patients underwent peripheral arterial reconstruction, and two patients had a sudden death, cause unknown.
Estimates of renal function and cardiovascular events
Patients who developed a CV event had substantially and significantly higher serum levels of creatinine and lower GFR at baseline (measured with the Cockcroft-Gault and MDRD formulas) as compared to patients who did not have a CV event ( Table 1 (Table S1 ).
Logistic regression analyses
Logistic regression analyses showed that a lower estimated renal function (calculated GFR with the MDRD-formula) was associated with an increased risk for a CV event, OR (95%-CI):
1.30 (1.14-1.49), per 5 ml/min/1.73 m 2 decrease in GFR (Table 2) . In other words, a decrease in the estimated GFR of 5 ml/min was associated with a 30% increase in risk of a CV event over the 3 year follow-up, which corresponds to a yearly risk increase of 11%. 
Discussion
This is the first prospective study that clearly shows a clinically relevant association between moderate renal dysfunction and an increased risk of CV events in RA. An 11% increased yearly risk of developing a CV event for every decrease in GFR of 5 ml/min, independent of traditional risk factors, is substantial. Thus far, only one cross-sectional study showed an association between renal dysfunction and CV disease risk factors in RApatients, such as total cholesterol, hypertension and previous CV disease. (18) In the last two decades it has become clear that patients with RA are at an increased risk of developing CV disease, largely independent of traditional cardiovascular risk factors. (1) RA could even be seen as a cardiovascular risk factor for CV disease, similar to diabetes mellitus. (19) In addition, recent reports suggest that CV disease risk assessment tools the effect size also appears stronger than in the general population and is comparable to that in DM.
As the association we found was independent of other risk factors, this suggests a causal role for the chronic inflammatory state present in both diseases. Other possibilities include renal dysfunction itself causing CV disease or other underlying pathological processes affecting both renal function and CV disease. In our data concomitant use of anti-inflammatory medication (especially non-steroidal anti-inflammatory drugs, but also glucocorticosteroids, etc) did not appear to explain our findings.
Strengths in our study include the prospective design, with low rates of loss to follow-up.
Also, we were able to test several factors one by one as confounders by studying the change in β coefficient of GFR before and after inclusion of the potential confounder. In the end only age, sex, systolic blood pressure, use of antihypertensive medication and/or statins, RA disease duration, health assessment questionnaire and presence of nodules proved to be confounders in our dataset and were thus included in the adjusted models. In addition, we performed subgroup analyses to investigate whether exclusion of previous CV disease changed the association between GFR and CV events in RA. Furthermore, we found a strong association between CV disease and both estimates of renal function (the Cockcroft-Gault and MDRD formulas). Several limitations merit attention. First, we were not able to adjust for residual confounding by recently discovered markers of both renal dysfunction and CV disease in RA-patients. One of these is uric acid, which is a predictor of CV disease in RA-patients (24) and has been linked with renal dysfunction in RApatients. (25) Moreover, we did not use a control population of healthy subjects and therefore were not able to compare the present findings in RA-patients with matched non-RA patients.
In conclusion, this study suggests that subclinical renal dysfunction is an independent risk factor for CV events in RA. A relatively minor decrease in estimated GFR may be associated with a substantial increase in CV morbidity. Therefore, clinicians should be aware that RA-patients with a decreased renal function are more prone to CV events.
